Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685750 · ClinicalTrials.gov registry record · NA
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
A NA study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT00685750: Clinical Trial NA study, sponsored by GlaxoSmithKline.
NCT00685750 is a NA study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 88 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685750, a NA study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of markers potentially predictive of clinical response to specific anticancer therapies.
Primary Outcome
The outcome presents the number of participants with expression of MAGE-A3 and NY-ESO-1 tumor antigens, after administration of standard of care treatment course compared to before administration
Interventions
- PROCEDURE Collection of tumor and blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2008-04-28 |
| Est. Completion | 2013-12-17 |
| Phase | NA |
Why NCT00685750 stopped before completion
NCT00685750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Collection of tumor and blood samples is the first listed.
NCT00685750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00685750 about?
NCT00685750 is a clinical study titled "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma". This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC ...
What is the current status of trial NCT00685750?
This trial is currently terminated. It is a NA study. The enrollment target is 88 participants. The study started on 2008-04-28. Estimated completion is 2013-12-17.
What interventions are being tested in trial NCT00685750?
The interventions under investigation include: Collection of tumor and blood samples (PROCEDURE).
Who is sponsoring clinical trial NCT00685750?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00685750's enrollment target sits among peer trials
88 972nd of 2000 higher than 1,027 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI